The Phase III ADAURA trial (63) provided compelling evidence that osimertinib significantly enhances DFS in patients with stage IB–IIIA NSCLC harboring sensitive EGFR mutations post-surgery (HR, 0.20, P < 0.001). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.